PDT-associated host response and its role in the therapy outcome

Lasers in Surgery and Medicine

Volumn 38, Issue 5, 2006, Pages 500-508

  Korbelik, Mladen ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Acute phase response; Adaptive immune response; Efferocytosis; Inflammation; Innate immunity; Photodynamic therapy

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; COLLAGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; DECAY ACCELERATING FACTOR; FIBRINOGEN; FIBRONECTIN; FICOLIN; FLAGELLIN; HEAT SHOCK PROTEIN; HISTAMINE; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; LIPOPOLYSACCHARIDE; LYSOPHOSPHOLIPID; MANNOSE BINDING LECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PATTERN RECOGNITION RECEPTOR; PENTRAXIN; PEPTIDOGLYCAN; PLASMA PROTEIN; PORPHYRIN; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; COMPLEMENT SYSTEM; CYTOTOXICITY; DENDRITIC CELL; GENE EXPRESSION; HOMEOSTASIS; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTE; PHAGOCYTOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TISSUE INJURY; TREATMENT OUTCOME; TUMOR; TUMOR VASCULARIZATION;

ACUTE-PHASE REACTION; ANIMALS; DISEASE MODELS, ANIMAL; IMMUNITY, INNATE; IMMUNITY, NATURAL; MICE; NEOPLASMS; PHOTOCHEMOTHERAPY;

EID: 33745685642     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20337     Document Type: Article

References (82)

1. Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG. Photoiradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975;55:115-121.
2. Delaney TF, Glatstein E. Photodynamic therapy of cancer. Compr Ther 1988;14:43-55.
3. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-157.
4. Korbelik M, Cecic I. Mechanism of tumor destruction by photodynamic therapy. In: Nalwa HS, editor. Handbook of Photochemistry and Photobiology, Vol. 4. Stevenson Ranch, CA: American Scientific Publishers; 2003. pp 39-77.
5. Korbelik M. Role of Toll-like receptors in photodynamic therapy-elicited host response. Proc SPIE 2004;5319:87-95.
6. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 1996;56:5647-5652.
7. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
8. Cecic I, Stott B, Sun J, Korbelik M. Relevance of innate immunity recognition of altered self in the induction of host response associated with photodynamic therapy. Recent Res Devel Cancer 2004;6:153-161.
9. Matzinger P. The danger model: A renewed sense of self. Science 2002;296:301-305.
10. Seong S-Y, Matzinger P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-478.
11. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298-300.
12. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: Relevance for tumor response. Cancer Res 2005;65:1018-1026.
13. Agrawal ML, Larkin HE, Zaidi SI, Mukhtar H, Oleinick NL. Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res 1993;53:5897-5902.
14. Andrews NW. Membrane repair and immunological danger. EMBO Rep 2005;6:826-830.
15. Beg AA. Endogenous ligands of Toll-like receptors: Implications for regulating inflammatory and immune responses. Trends Immunol 2002;23:509-512.
16. Musser DA, Wagner JM, Weber FJ, Datta-Gupta M. The binding of tumor localizing porphyrins to a fibrin matrix and their effects following photoirradiation. Res Commun Chem Pathol Pharmacol 1980;28:505-525.
17. Musser DA, Wagner JM, Datta-Gupta M. The interaction of tumor localizing porphyrins with collagen and elastin. Res Commun Chem Pathol Pharmacol 1982;36:251-259.
18. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.
19. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF III. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-10233.
20. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 2001;167:2887-2894.
21. Medzhitov R, Janeway CA. Innate immunity: Impact on the adaptive immune response. Curr Opin Immunol 1997;9: 4-9.
22. Medzhitov R, Janeway CA. Innate immunity. N Engl J Med 2000;343:338-344.
23. Korbelik M, Stott B, Sun J, Cecic I. Localized production of complement proteins in tumors treated by photodynamic therapy. Mol Immunol 2004;41:260.
24. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-1098.
25. Cecic I, Korbelik M. Deposition of complement proteins on cells treated by photodynamic therapy in vitro. J Environ Pathol Toxicol Oncol 2006;25:189-203.
26. Korbelik M, Merchant S, Sun J, Stott B, Cecic I. Acute phase response induced following tumor treatment by photodynamic therapy: Relevance for the therapy outcome. Proc SPIE (Vol 6087, in press).
27. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass H. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst 1990;82:34-39.
28. Karrer S, Bosserhoff AK, Weiderer P, Landhaler M, Szeimies RM. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J Dermatol 2004;151:776-783.
29. Cecic I, Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 2002;183:43-51.
30. Korbelik M, Sun J, Cecic I, Serrano K. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors. Photochem Photobiol Sci 2004;3:812-816.
31. Cecic I, Serrano K, Gyongyossy-Issa M, Korbelik M. Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy. Cancer Lett 2005;225:215-223.
32. Cecic I, Sun J, Korbelik M. Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells. Photochem Photobiol. (in press).
33. Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumor by Photofrin-based photodynamic therapy. Br J Cancer 1995;71:549-555.
34. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997;57:3904-3909.
35. Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol 2001;74:712-720.
36. Sun J, Cecic I, Parkins CS, Korbelik M. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors. Photochem Photobiol Sci 2002;1:690-695.
37. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol 2000;190:343-348.
38. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-328.
39. Dennis EJ, Dolmans GJ, Fukumura D, Jain RK. Photodynamic therapy of cancer. Nat Rev Cancer 2003;3:380-387.
40. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000;28:S77-S80.
41. Korbelik M, Parkins CS, Shibuya H, Cecic I, Stratford M, Chaplin DJ. Nitric oxide production by tumor tissue: Impact on the response to photodynamic therapy. Br J Cancer 2000; 82:1835-1843.
42. Korbelik M, Sun J. Ischemia-reperfusion injury in photodynamic therapy-treated mouse tumors. Br J Cancer 2003; 88:760-766.
43. Ren Ym, Savill J. Apoptosis: The importance of being eaten. Cell Death Differ 1998;5:563-568.
44. deCathelineau AM, Henson PM. Programmed cell death: Chapter 8. The final step in programmed cell death: Phagocytes carry apoptotic cells to the grave. Essays Biochem 2003;39:105-117.
45. Bratton DL, Henson PM. Autoimmunity and apoptosis: Refusing to go quietly. Nat Med 2005;11:26-27.
46. Elward K, Gasque P. "Eat me" and "don't eat me" signals govern the innate immune response and tissue repair in the CNS: Emphasis on the critical role of the complement system. Mol Immunol 2003;40:85-94.
47. Roos A, Xu W, Castellano G, Nauta AJ, Garred P, Daha MR, van Kooten C. A pivotal role for innate immunity in the clearance of apoptotic cells. Eur J Immunol 2004;34:921-929.
48. Gardal SJ, Mcphillips KA, Frash SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenburg P-E, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005;123:321-334.
49. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
50. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454.
51. Jolles JC, Ott MJ, Straight RC, Lynch DH. Systemic immunosuppression induced by peritoneal photodynamic therapy. Am J Obstet Gynecol 1988;158:1446-1453.
52. de Vree WJA, Essers MC, Koster JF, Sluiter W. Role of interleukin 1 and granulocyte colony-stimulating factor in Photofrin-based photodynamic therapy of rat rhabdomyosarcoma. Cancer Res 1997;57:2555-2558.
53. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, Wang WC, Unger E, Henderson BW. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;88:1772-1779.
54. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999;137: 91-98.
55. Cecic I, Stott B, Korbelik M. Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int Immunopharmacol (in press).
56. Henson PM. Dampening inflammation. Nat Immunol 2005;6:1179-1181.
57. Xiao YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, Bratton DL, Henson PM. Cross-talk between ERK and p38 MAPK mediates selective suppression of proinflammatory cytokines by transforming growth factor-β. J Biol Chem 2002;277:14884-14893.
58. Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997;100:2443-2448.
59. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to nucleus. Cell 2003;113:685-700.
60. O'Kane S, Ferguson MWJ. Transforming growth factor βs and wound healing. Int J Biochem Cell Biol 1997;29:63-78.
61. Golpon HA, Fadok VA, Taraseviciene-Stewart L, Scerbavicius R, Sauer C, Weite T, Henson PM, Voelkel NF. Life after corpse engulfment: Phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J 2004;18:1716-1718.
62. Ferrario A, von Thiel KF, Rucker N, Schwartz MA, Gill PS, Gomer CJ. Anti-angiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000;60:4066-4069.
63. Ferrario A, Fisher AM, Rucker N, Gomer CJ. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005;65:9473-9478.
64. Ferrario A, Chantrain CF, von Thiel K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerk YA, Gomer CJ. The matrix metalloproteinase inhibitor Prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004;64:2328-2332.
65. Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res 1999;59:1941-1946.
66. Canti G, De Simone A, Korbelik M. Photodynamic therapy and the immune system in experimental oncology. Photochem Photobiol Sci 2002;1:79-80.
67. Abdel-Haday ES, Martin-Hirsh P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001;61:192-196.
68. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542-3549.
69. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001; 22:141-148.
70. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not to primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434.
71. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002;62:1604-1608.
72. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother (in press).
73. Mevorach D. The role of death-associated molecular patterns in the pathogenesis of systemic lupus erythematosus. Rhem Dis Clin North Am 2004;30:487-504.
74. Cocco RE, Ucker DS. Distinct modes of macrophage recognition for apoptotic and necrotic cells are not specified exclusively by phosphatidylserine exposure. Mol Biol Cell 2001;12:919-930.
75. Melcher A, Gough M, Todryk S, Vile R. Apoptosis or necrosis for tumor immunotherapy: What's in a name? J Mol Med 1999;77:824-833.
76. Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, Voll RE, Gaipl US, Bertling W, Pöschl E, Kalden JR, Manfredi AA, Herrmann M. Inhibition of phosphatidylserine recognition heightens the immunogeneicity of irradiated lymphoma cells in vivo. J Exp Med 2004; 200:1157-1165.
77. Gollnick SO, Mazzacua A, Vaughan L, Owczarczak B, Maier P, Henderson BW. Photodynamic therapy (PDT) treatment enhances tumor cell antigenicity. Proc SPIE 2001;4257: 25-28.
78. Clark PR, Ménoret A. The inducible Hsp70 as a marker of tumor immunogenicity. Cell Stress Chaperones 2001;6:121-125.
79. Chen X, Tao Q, Yu H, Zhang L, Cao X. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol Lett 2002;84:81-87.
80. Asea A. Chaperone-induced signal transduction pathways. Exerc Immunol Rev 2003;9:25-33.
81. Linderoth NA, Popowicz A, Sastry S. Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94). J Biol Chem 2000;275: 5472-5477.
82. Carrol MC. The complement system in regulation of adaptive immunity. Nature Immunol 2004;5:981-986.